Pasithea Therapeutics (KTTA) News Today → The most important AI company you've never heard of (From Manward Press) (Ad) Free KTTA Stock Alerts $6.65 0.00 (0.00%) (As of 05:22 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 11:05 AM | msn.comKTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024May 14 at 2:39 AM | americanbankingnews.comPasithea Therapeutics (NASDAQ:KTTA) Trading Down 9.5%April 29, 2024 | globenewswire.comPasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingApril 24, 2024 | globenewswire.comPasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersFebruary 15, 2024 | marketbeat.comTrading was temporarily halted for "KTTA" at 02:02 PM with a stated reason of "LULD pause."February 13, 2024 | finance.yahoo.comPasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004January 8, 2024 | finance.yahoo.comPasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJanuary 2, 2024 | msn.comPasithea Jumps as FDA Grants IND Status to Cancer TreatmentJanuary 2, 2024 | markets.businessinsider.comPasithea Therapeutics' IND Application For PAS-004 Gets FDA AcceptanceJanuary 2, 2024 | seekingalpha.comPasithea conducts 1-for-20 reverse stock split, gets FDA okay for studyJanuary 2, 2024 | finance.yahoo.comPasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsJanuary 1, 2024 | benzinga.comPasithea Therapeutics Stock (NASDAQ:KTTA) Dividends: History, Yield and DatesJanuary 1, 2024 | marketbeat.comTrading was temporarily halted for "KTTA" at 07:12 PM with a stated reason of "News pending."December 28, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023December 19, 2023 | finance.yahoo.comPasithea Therapeutics Announces Results from 2023 Annual MeetingDecember 13, 2023 | msn.comWhy Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?December 11, 2023 | msn.comNeurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's WhyDecember 11, 2023 | markets.businessinsider.comPasithea Announces Positive In Vivo Preclinical Data For PAS-004December 11, 2023 | msn.comPasithea stock soars as high as 190% on preclinical dataDecember 11, 2023 | investorplace.comWhy Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?December 11, 2023 | finance.yahoo.comPasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNovember 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNovember 29, 2023 | msn.comPasithea stock jumps 12% on update for anti-tumor drug PAS-004November 29, 2023 | markets.businessinsider.comPasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical DevelopmentNovember 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNovember 9, 2023 | finance.yahoo.comPasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSSeptember 14, 2023 | finance.yahoo.comPasithea Therapeutics Corp. Announces Final Results of Tender OfferSeptember 7, 2023 | finance.yahoo.comPasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceAugust 1, 2023 | finance.yahoo.comPasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor functionJuly 20, 2023 | benzinga.comWhat's Happening With Pasithea Therapeutics Stock Today?July 20, 2023 | finance.yahoo.comPasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashJuly 20, 2023 | finance.yahoo.comPasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.July 20, 2023 | finance.yahoo.comPasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashJune 30, 2023 | finance.yahoo.comPasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of DirectorsJune 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004June 5, 2023 | barrons.comPasithea Therapeutics Corp.June 5, 2023 | marketbeat.comTrading was temporarily halted for "KTTA" at 08:06 AM with a stated reason of "News pending."June 1, 2023 | finanznachrichten.deFinancialnewsmedia.com: Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029June 1, 2023 | finance.yahoo.comPasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis ConferenceMay 14, 2023 | finance.yahoo.comPasithea Therapeutics First Quarter 2023 Earnings: US$0.13 loss per share (vs US$0.068 loss in 1Q 2022)May 3, 2023 | finance.yahoo.comPasithea Therapeutics to Participate in EF Hutton Inaugural Global ConferenceApril 1, 2023 | seekingalpha.comPasithea Therapeutics files for $15M mixed shelf offeringMarch 2, 2023 | finance.yahoo.comPasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual MeetingFebruary 23, 2023 | finance.yahoo.comPasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)February 16, 2023 | finance.yahoo.comPasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine AwardJanuary 25, 2023 | seekingalpha.comKTTA Pasithea Therapeutics Corp.January 18, 2023 | finance.yahoo.comPasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004January 16, 2023 | finance.yahoo.comPasithea Therapeutics Corp. (KTTA)December 14, 2022 | finance.yahoo.comMajority of Stockholders Support Pasithea Directors at Special MeetingDecember 6, 2022 | finance.yahoo.comPasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address The most important AI company you've never heard of (Ad)Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products. Get the full story on this secret AI company poised for massive growth KTTA Media Mentions By Week KTTA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KTTA News Sentiment▼0.930.55▲Average Medical News Sentiment KTTA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KTTA Articles This Week▼40▲KTTA Articles Average Week Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Universe Pharmaceuticals News Can-Fite BioPharma News Hepion Pharmaceuticals News eFFECTOR Therapeutics News Vaccinex News Cyclerion Therapeutics News Processa Pharmaceuticals News TransCode Therapeutics News Shuttle Pharmaceuticals News Bionomics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KTTA) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
